PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ: STEM) announced today that its president and CEO, Martin McGlynn, was recently featured on BioBusiness.TV’s “Stem Cell Review” discussing the Company’s therapeutic product development programs, including the promise of human neural stem cells and the broad potential application of the Company’s lead product candidate, HuCNS-SC® cells, in a variety of central nervous system (CNS) disorders. The Stem Cell Review is a 10-part series produced by BioBusiness.TV that covers the science, medical applications, and business of stem cells, and features leading authorities in the field.
